At the 2026 Annual Meeting of Stockholders held on June 5, 2026, Axsome Therapeutics, Inc. stockholders elected Mark Saad and Susan Mahony, Ph.D., MBA to serve as Class II directors. The meeting also resulted in the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm for the 2026 fiscal year and the approval of executive compensation on a non-binding advisory basis. Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.
